Modified-Release Gamma-Hydroxybutyrate for Once-Nightly Bioavailability
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Existing modified release formulations of gamma-hydroxybutyrate suffer from low bioavailability and inconvenience due to the need for multiple doses and high sodium intake, failing to approximate the pharmacokinetic profile of twice-nightly immediate release sodium oxybate administration.
Innovation Solution
A modified release formulation of gamma-hydroxybutyrate that rapidly releases half of its dose in 0.1N hydrochloric acid and the other half in phosphate buffer pH 6.8, achieving bioavailability comparable to twice-nightly immediate release sodium oxybate across a range of therapeutic doses.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Ease of operation
If modified release formulations of gamma-hydroxybutyrate are used, then the convenience of administration is improved (once-nightly dosing), but the bioavailability is reduced compared to twice-nightly immediate release administration
Solution Approach 1:
The formulation is divided into two distinct portions: an immediate release portion that rapidly dissolves to provide initial therapeutic effect, and a modified release portion that dissolves gradually to maintain therapeutic levels throughout the night. This segmentation allows the single nightly dose to achieve pharmacokinetic profiles comparable to twice-nightly dosing.
Solution Approach 2:
The invention changes the dissolution parameters of the formulation by using pH-dependent release mechanisms. The modified release portion is designed to dissolve at different rates in acidic versus neutral pH environments, allowing controlled release of gamma-hydroxybutyrate throughout the dosing interval while maintaining high bioavailability.
2Reliability
If immediate release sodium oxybate is administered twice nightly, then the pharmacokinetic profile is optimized, but the treatment complexity increases
Solution Approach 1:
The invention merges the functions of two separate immediate release doses into a single modified release formulation. The combination of immediate release and modified release portions in one dosage form eliminates the need for multiple administration events while maintaining the therapeutic benefits of optimized pharmacokinetics.
3Reliability
If higher doses of gamma-hydroxybutyrate are administered to compensate for low bioavailability, then the therapeutic effectiveness may be maintained, but the adverse reactions increase
Solution Approach 1:
The modified release portion provides continuous release of gamma-hydroxybutyrate throughout the dosing interval, maintaining steady therapeutic levels without the peaks and troughs associated with immediate release formulations. This continuous action ensures therapeutic effectiveness while avoiding the high peak concentrations that cause adverse reactions.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The formulation provides improved pharmacokinetic profiles with reduced adverse reactions, allowing once-nightly administration and lower sodium intake, while maintaining therapeutic effectiveness and safety.
Implementation Method 1
rapidly releases half of its dose in 0.1N hydrochloric acid and the other half in phosphate buffer pH 6.8
Data Source
AI summary
Modified release formulations of gamma-hydroxybutyrate having improved dissolution and pharmacokinetic properties are provided, and therapeutic uses thereof.